Oppenheimer Initiates Coverage On Harmony Biosciences with Outperform Rating, Announces Price Target of $55
December 1, 5:59 AM
Oppenheimer analyst Francois Brisebois initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $55.
November 9, 8:49 AM
Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.28 by 82.14 percent. This is a 464.29 percent increase over losses of $(0.14) per share
November 9, 5:41 AM
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
October 19, 2:35 PM
Toward the end of trading Tuesday, the Dow traded up 0.33% to 35,374.03 while the NASDAQ rose 0.54% to 15,103.67. The S&P also rose, gaining 0.55% to 4,511.35.
October 19, 12:11 PM
Midway through trading Tuesday, the Dow traded up 0.47% to 35,423.05 while the NASDAQ rose 0.59% to 15,110.79. The S&P also rose, gaining 0.61% to 4,513.69.
October 19, 10:08 AM
Following the market opening Tuesday, the Dow traded up 0.29% to 35,361.89 while the NASDAQ rose 0.31% to 15,068.75. The S&P also rose, gaining 0.39% to 4,503.81.
S&P Dow Jones Indices Announces ‘Kite Realty Group Trust Set to Join S&P MidCap 400; Harmony Biosciences Holdings & LendingTree to Join S&P SmallCap 600’
October 18, 5:18 PM